Looks like Pfizer wants to buy a Swedish company who provides a treatment for neonatal-onset multisystem inflammatory disease, (NOMID). NOMID belongs to a family of conditions known as Cryopyrin-Associated Periodic Syndromes, or CAPS. A mutation in the NLRP-3 gene is what causes CAPS.
According to Seeking Alpha contributor Douglas W. House, Sobi (Swedish Orphan Biovitrum), the company that makes interleukin-1 (IL-1) antagonist Kineret (anakinra), has a price tag of $4.3 billion. Kineret treats NOMID.
Surely the above picture doesn’t resemble their uniforms. But what else is Sobi cooking? Read more…
